Clinical TrialJul 6, 2026, 08:34 AM
Moleculin CEO Discusses Positive Annamycin Trial Results
AI Summary
Moleculin Biotech, Inc. announced that its Chairman and CEO, Walter Klemp, discussed positive preliminary unblinded efficacy results from the first 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial. The trial is evaluating Annamycin for relapsed or refractory acute myeloid leukemia (R/R AML). Mr. Klemp provided insights into the early efficacy trends, key data, and the commercial opportunity for Annamycin.
Key Highlights
- CEO Walter Klemp discussed positive preliminary unblinded efficacy results from the MIRACLE trial.
- Results are from the first 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial.
- The trial evaluates Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML).
- Mr. Klemp provided perspective on early efficacy trends across both Annamycin treatment arms.
- He summarized key data and discussed the commercial opportunity for Annamycin.
Price Impact
More from MBRX